Page last updated: 2024-11-07

s-nitroso-n-acetylcysteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S-nitroso-N-acetylcysteine (SNAC) is a nitric oxide (NO) donor that has been studied for its potential therapeutic effects. It is synthesized by the reaction of N-acetylcysteine (NAC) with an NO donor, such as sodium nitrite. SNAC has been shown to have a variety of biological effects, including vasodilation, anti-inflammatory activity, and neuroprotection. It is studied for its potential to treat various diseases, including cardiovascular disease, stroke, and Alzheimer's disease. The importance of SNAC lies in its ability to deliver NO to specific tissues and cells, potentially offering targeted therapeutic benefits. However, further research is needed to understand the full potential and limitations of SNAC as a therapeutic agent.'

S-nitroso-N-acetylcysteine: activates bovine coronary arterial & rat hepatic soluble guanylate cyclase; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122058
SCHEMBL ID221192
MeSH IDM0083731

Synonyms (16)

Synonym
56577-02-7
l-cysteine, n-acetyl-s-nitroso-
(2r)-2-acetamido-3-nitrososulfanylpropanoic acid
s-nitroso-n-acetylcysteine
unii-oz9124l8zv
oz9124l8zv ,
SCHEMBL221192
s-nitroso-n -acetyl-l-cysteine
l-cysteine, n-acetyl-, nitrite (ester)
(r)-2-acetamido-3-(nitrosothio)propanoic acid
n-acetyl-s-nitroso-l-cysteine
DTXSID20972018
n-(1-hydroxyethylidene)-s-nitrosocysteine
(r)-2-acetamido-3-(nitrosothio)propanoicacid
(2r)-2-acetamido-3-(nitrososulfanyl)propanoic acid
AKOS040746358

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The findings indicate that 1) SNAC does not influence contractile function of EDL muscle not subjected to ischemia-reperfusion, 2) SNAC significantly protects the contractile function of ischemic skeletal muscle against reperfusion injury in the early reperfusion period, and 3) the protective role of SNAC is critically dosage dependent; protection is lost at higher doses."( Effects of S-nitroso-N-acetylcysteine on contractile function of reperfused skeletal muscle.
Chen, LE; Nasser, RM; Seaber, AV; Stamler, JS; Urbaniak, JR, 1998
)
0.69
" SNAC reduced the medium arterial pressure in a dose-response manner in both normotensive and hypertensive animals."( Characterization of the hypotensive effect of S-nitroso-N-acetylcysteine in normotensive and hypertensive conscious rats.
de Oliveira, MG; Krieger, MH; Ricardo, KF; Shishido, SM, 2002
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (5.36)18.7374
1990's16 (28.57)18.2507
2000's18 (32.14)29.6817
2010's17 (30.36)24.3611
2020's2 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.66 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]